| Our Company |
|
About Our Company  Biomagnetics Diagnostics Corporation (OTC: BMGP) through its wholly owned subsidiary,
Biospectrum Technologies holds revolutionary patented technologies that can potentially re-vitalize the diagnostics industry.
The first product being readied for market is the High Throughput Screening - Magnetic Testing Platform (HTS-MTP). This diagnostic equipment is designed to detect the target virus by measuring and defining a single paramagnetic microsphere attached to each virus molecule in a fraction of the time and cost of existing immuno assays. It is important to note that the HTS-MTP is designed to detect both bacterial and viral pathogens as well as drugs of abuse using a medium of blood, serum, saliva, urine, hormonal or even spinal fluid. This is accomplished through the use of proprietary electronics, and chemistry which include specially designed sensors, which will detect paramagnetic-microspheres coated with specific antibodies, and will bind to any antigen (or other specified target) within the sample. Specific software programs will be designed for each type of pathogenic assay. Additionally, no current screening, or confirmatory tests, have the ability to measure viral load; a critical measurement in developing drugs and vaccines and determining the effectiveness of health care treatments. The HTS-MTP is designed to detect the virus and count the viral load in a matter of minutes, and has the capabilities of screening many more assays per hour, at a fraction of the cost of current technology. This will revolutionize the diagnostics industry and be of significant importance to blood banks around the world. Company management has identified
certain immediacy in the Latin American and Asian markets. Therefore,
initial Company efforts will focus upon conducting clinical trials and
product registrations, not just in the United States but in Mexico, Thailand, China
and Sweden (Sweden will register our products throughout Europe) as well. |
